SHINGRIX (GlaxoSmithKline Australia Pty Ltd)
Product name
SHINGRIX
Date registered
Evaluation commenced
Decision date
Approval time
207 working days (255)
Active ingredients
recombinant Varicella Zoster Virus glycoprotein E antigen
Registration type
NCE/NBE
Indication
SHINGRIX (powder for suspension and suspension for injection) is indicated for the prevention of herpes zoster and post-herpetic neuralgia in adults 50 years of age or older.